Add this topic to your myFT Digest for news straight to your inbox
You select the topic, we deliver the news.
Shareholders had been unhappy with company performance for some time
Plenty of fiddly operational stuff to get on with
Pfizer leaves door ajar for AstraZeneca board to change its mind
UK government denies ‘cheerleading’ for Pfizer’s bid
Not clear big mergers increase productivity in R&D, chairman says
Institutional investors signal interest if price is right
Questions surround valuation and truckmaker’s future
The same global insight. Faster than ever before on all your devices.